BIGBEAR
PHARMACEUTICAL
Low incidence of peripheral edema.
Low hepatotoxicity.
AuthenticGuaranteeFast DeliveryPrivacy On April 24, 2022, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for capmatinib (Tabr···【More】
Update: 26 Mar,2026Source: BigbearViews: 89
The US FDA has approved the targeted anticancer drug Tabrecta (capmatinib, formerly known as INC280, carmatinib) for the treatment of adult patients w···【More】
Update: 26 Mar,2026Source: BigbearViews: 84
On June 22, 2022, Novartis announced that the European Commission (EC) has approved Tabrecta (capmatinib) as a monotherapy for adult patients with adv···【More】
Update: 26 Mar,2026Source: BigbearViews: 114
Novartis recently announced that the U.S. FDA has approved the targeted anticancer drug Tabrecta (capmatinib, formerly known as INC280) for the treatm···【More】
Update: 26 Mar,2026Source: BigbearViews: 86
On August 10, 2022, the U.S. Food and Drug Administration (FDA) announced the granting of standard approval to Tabrecta (carmatinib) for the treatment···【More】
Update: 26 Mar,2026Source: BigbearViews: 86
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
